A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers.
Liu KJ, Guan ZZ, Liang Y, Yang XQ, Peng J, Huang H, Shao QX, Wang MZ, Zhu YZ, Wu CP, Wang SB, Xiong JP, Bai YX, Yu SY, Zhang Y, Hu XH, Feng JF, Wu SX, Jiao SC, Zhou CC, Wang J, Wu HY.
Liu KJ, et al. Among authors: wu hy, wu sx, wu cp.
Arch Med Sci. 2014 Aug 29;10(4):717-24. doi: 10.5114/aoms.2014.44862.
Arch Med Sci. 2014.
PMID: 25276156
Free PMC article.